What clinicians should know about a published randomized study on cartilage regeneration biomarkers, and how it changes the joint health conversation.*

For decades, the consensus held that adult cartilage cannot regenerate without invasive intervention. The biology pointed in one direction: cartilage has no direct blood supply, its natural repair capacity is limited, and the standard recommendation for joint discomfort has been glucosamine and chondroitin (despite a research base that has produced inconsistent results across multiple large meta-analyses). For people walking into a clinic with joint discomfort, the available supplement options have looked the same for a long time.

That assumption is now being challenged. A randomized, double-blind, placebo-controlled human study on Cartigenix HP® with RestorCel® from Calroy Health Sciences showed measurable increases in cartilage regeneration biomarkers and decreases in cartilage degeneration biomarkers within 90 days — alongside a 64% improvement in WOMAC pain scores and a 50% improvement in walking distance.* Across three published human trials covering more than 1,600 participants, individuals taking the formulation experienced an average 67% reduction in pain scores and an average 50% increase in walking distance.*†

This guide walks clinicians through what the research showed, how cartilage regeneration was measured, where the formulation fits alongside conventional joint supplements, and how to integrate it into a comprehensive joint health protocol.

Shifting the Long-Held Assumption: Adult Cartilage Cannot Regenerate

Articular cartilage is the smooth, resilient connective tissue that cushions the ends of bones in joints. It allows for low-friction movement and absorbs the mechanical load of everyday activity. It is also one of the few tissues in the body without a direct blood supply, which has long been understood to limit its capacity for natural repair after wear or injury.

This biological reality shaped the conventional view that once cartilage thinned or lost structural integrity, the options were limited to managing comfort only. Surgical interventions could replace tissue or attempt repair, but the idea that adult cartilage could measurably regenerate through dietary supplement support was, until recently, considered outside the scope of what dietary supplements could do.*

That view is shifting. A randomized, double-blind, placebo-controlled study on Cartigenix HP with RestorCel showed meaningful increases in cartilage regeneration biomarkers (Vaidya,2025).*

The need for this type of support reaches beyond those experiencing discomfort. Recent imaging research suggests that structural cartilage changes precede joint discomfort more often than previously assumed. In a Framingham MRI analysis of adults without symptoms, 89% had knee abnormalities visible on imaging. The implication is that proactive cartilage support is relevant for many adults well before joint discomfort enters the conversation. The question becomes what kind of support has research behind it.

What People Actually Want: Joint Comfort That Goes Beyond Masking Pain*

Most adults walking into a clinic with joint concerns are there because something hurts. Stairs feel harder. Recovery after a hike takes longer. The first few minutes of activity feel stiffer than they used to. The immediate goal is comfort.

That goal is legitimate, and it is what the joint supplement category has historically tried to address. Comfort gets managed at the surface, while the cartilage continues its trajectory.

The research on Cartigenix HP with RestorCel shows that pain score reduction, cartilage biomarkers, and functional improvements can be improved in the same study population. In the 2025 Vaidya randomized, placebo-controlled trial, participants experienced significant reductions in pain scores and significant improvements in walking distance, alongside measurable shifts in cartilage regeneration biomarkers, all within 90 days.* (Vaidya, 2025). The pain score reduction was statistically significant.* The biomarker data pointed to measurable regeneration happening at the tissue level.*†. Both outcomes were observed in the same study, in the same participants, on the finished product.

Why Glucosamine and Chondroitin Have Been the Default — and What the Evidence Shows

Glucosamine and chondroitin have dominated the joint supplement category for decades. Roughly 6.5 million Americans take glucosamine annually. Both ingredients are naturally present in cartilage matrix, and the rationale for supplementation is mechanistically plausible: provide raw material, support the matrix.

Unfortunately, the clinical evidence has not consistently supported the rationale. Multiple meta-analyses (including reviews published in JAMA, Inflammopharmacology, and Archives of Orthopaedic and Trauma Surgery) have found small or inconsistent effects of glucosamine and chondroitin compared to placebo, with significant variability across product quality and formulation. After decades of research and multiple large reviews, the data does not strongly support the effectiveness of glucosamine and chondroitin for joint comfort or function.

This was the gap, before the research on Cartigenix HP with RestorCel. Three published human trials, including a randomized, placebo-controlled study, showed outcomes the conventional category had not been able to demonstrate.*†

“I recommended glucosamine and chondroitin to patients for years. It was the standard of care, and there wasn’t much else to point to. The honest answer when patients asked if it would work was ‘maybe.’ What’s different now is that we have published research, including a placebo-controlled study, with measurable outcomes on a new supplement. That gives clinicians and patients confidence.” — Tom Bayne, DC, educator with Calroy Health Sciences

What the Research Showed: A Randomized, Placebo-Controlled Study on Cartilage Regeneration Biomarkers

The 2025 Vaidya study was a randomized, double-blind, multicenter, placebo-controlled trial of 62 adults aged 40 to 65, conducted over 90 days, evaluating Cartigenix HP with RestorCel against placebo. Outcomes included validated pain and functional measures alongside cartilage biomarker analysis.* (Vaidya, 2025).

The results, as reported in the published study*†

• 64% improvement in WOMAC pain scores
• 50% improvement in walking distance (6-Minute Walk Test)
• Significant increases in cartilage regeneration biomarkers (PIIANP and PIICP)
• Significant decreases in cartilage degeneration biomarkers (CTX-II and COMP)
• Noticeable improvements reported by many participants as early as 15 days
• No adverse events reported

The biomarker data is what makes this study notable. PIIANP and PIICP are validated markers of type II procollagen which is the building block of cartilage matrix. An increase in these biomarkers in a research setting indicates that cartilage matrix regeneration was occurring.* These biomarkers are research tools, not clinical lab tests a healthcare provider would order in routine practice. Their presence in the study data provides an objective signal that something was happening at the structural level of cartilage, not only in how participants described their experience.

“What stands out about the Vaidya study isn’t just the pain reduction or the walking distance. Those are meaningful patient-reported metrics. But the biomarker data is the real shift. PIIANP and PIICP increasing in a placebo-controlled setting tells us something was happening at the tissue level, not just in how participants felt. That’s the distinction practitioners have been waiting for in this category.” — Tom Bayne, DC, educator with Calroy Health Sciences

The Full Evidence Base: Three Published Human Studies

Cartigenix HP with RestorCel has been evaluated in three published human studies covering more than 1,700 participants across multiple study designs.*†

• Desai 2022 (Prospective Study)

A prospective study of 1,236 adults aged 19 to 75 over 90 days. Participants showed a 72.5% improvement in WOMAC pain scores along with an increase in quality-of-life measures.*†

• Desai 2024 (Observational Study)

An observational study of 394 adults aged 18 and over, conducted over 90 days. Participants showed a 75% improvement in WOMAC pain scores and a 78% improvement in quality-of-life scores.*†

• Vaidya 2025 (Randomized, Double-Blind, Placebo-Controlled Trial)

A randomized, double-blind, multicenter, placebo-controlled study of 62 adults aged 40 to 65 over 90 days. Participants showed a 64% improvement in WOMAC pain scores, a 50% improvement in walking distance, and significant increases in cartilage regeneration biomarkers.*

Across all three studies, participants experienced an average 67% reduction in pain scores, an average 50% increase in walking distance, and (in the placebo-controlled study) measurable cartilage regeneration biomarkers, with noticeable improvements reported as early as 15 days. No adverse events were reported in any of the three studies.*†

These outcomes are formulation-specific. They were measured on Cartigenix HP with RestorCel as a finished product, not extrapolated from research on individual ingredients.

The RestorCel Formulation: 13 Standardized Bioactives

At the core of Cartigenix HP is RestorCel, a proprietary, clinically studied blend of 13 bioactive compounds derived from two source extracts: Boswellia serrata (Indian frankincense) and Apium L. graveolens (North Indian celery seed). These two botanicals were selected for their synergistic effects on cartilage support, joint comfort, and healthy mobility.*

Boswellia serrata

In its whole form, a resin-derived extract long used to support musculoskeletal comfort and function. The boswellia components in RestorCel are standardized via HPLC-PDA to contain at least 40% total boswellic acids, including AKBA, KBA, and BBA, plus serratol, tirucallic acids, and others. Standardization matters because boswellic acid content varies considerably between boswellia species and even between extracts of the same species. The most rigorously researched species for joint health is Boswellia serrata.*

Celery Seed Extract (Apium graveolens)

In its whole form, often used in cooking and for culinary purposes. For Cartigenix HP, the extract is standardized for compounds including apiin and 3-n-butylphthalide (3nB). The celery seed component contributes complementary bioactive compounds that work synergistically with the Boswellia component to support cartilage and joint health.*

The 13 standardized bioactives in RestorCel — including serratol, boswellic acids, tirucallic acids, apiin, bergapten, and others — were selected and standardized in precise ratios for their combined effects on cartilage and joint health. This combination, in these specifications, is found exclusively in RestorCel.*

How Clinicians Are Integrating Cartigenix HP with RestorCel Into Joint Health Protocols

A 90-day supplementation period aligns with the observed timeline of biomarker change in the published research. For practitioners building a comprehensive joint health protocol, supplements complement lifestyle interventions, prescription medications, and other adjunctive interventions.

“When I work with someone on a joint health protocol, the supplement is one piece, but movement, sleep, and nutrition matter just as much. What I tell patients about Cartigenix HP is that the published research used a 90-day window for a reason. If you’re going to commit to a supplement, commit to giving it the time the studies gave it.” — Tom Bayne, DC, educator with Calroy Health Sciences

Suggested Protocol Timeline

• Day 1: Baseline assessment and supplement start (1 capsule of Cartigenix HP with RestorCel twice daily with food)
• Day 15 / 30 / 45: Check-in and progress review using validated tools such as WOMAC, KOOS, or a 0–10 pain scale
• Day 90: Evaluation of progress and recommendation adjustments based on results

Components of a Comprehensive Joint Health Plan

• Science-backed supplementation, using formulas with human studies on the finished product, like Cartigenix HP.*
• Consistent weekly movement (walking, hiking, strength training, range-of-motion work) — regular movement supports blood circulation, synovial fluid vitality, and overall joint function
• Joint-supportive nutrition emphasizing antioxidant-rich whole foods, polyphenols, and omega-3-dense foods
• Healthy sleep routines, hydration, and stress management as foundational supports

Calroy backs Cartigenix HP with RestorCel with a 45-day, 100% money-back guarantee, which gives individuals a meaningful trial window. Each bottle provides a 30-day supply at the studied dose.

Frequently Asked Questions

Can cartilage really regenerate with supplements?

For decades, the consensus held that adult cartilage cannot regenerate without invasive intervention. That view is now being challenged. A randomized, double-blind, placebo-controlled human study on Cartigenix HP with RestorCel showed significant increases in cartilage regeneration biomarkers and decreases in cartilage degeneration biomarkers within 90 days, alongside significant reductions in pain scores and improvements in walking distance.*† This is the first dietary supplement formulation that we know of with placebo-controlled human research showing measurable changes in cartilage regeneration biomarkers.*

Do glucosamine and chondroitin work for joint comfort or cartilage repair?

Multiple meta-analyses have found small or inconsistent effects of glucosamine and chondroitin compared to placebo. Some individuals report comfort improvements, but research does not consistently support meaningfully improved comfort or functional improvement.

How is cartilage regeneration measured in clinical research?

Cartilage regeneration is measured in research using a combination of validated pain scales (such as the WOMAC Pain Scale), functional tests (such as the 6-Minute Walk Test for walking distance), and cartilage biomarkers measured in blood (such as PIIANP and PIICP, which reflect type II procollagen synthesis). The strongest study designs are randomized, double-blind, placebo-controlled trials that compare the formulation against placebo across a defined study window. Cartilage biomarkers are research tools and are not typically ordered in routine clinical practice.

How long does it take to notice changes in joint comfort with cartilage-focused supplements?

In the three published research studies on Cartigenix HP with RestorCel, many participants reported noticeable improvements in joint comfort within 15 days, with statistically significant results at 90 days.*† Individual experiences may vary. To align with the published research, a 90-day period is generally recommended.

What clinical research supports Cartigenix HP with RestorCel?

Cartigenix HP with RestorCel has been evaluated in three published human studies: the 2022 Desai prospective study with 1,236 participants, the 2024 Desai observational study with 394 participants, and the 2025 Vaidya randomized, double-blind, placebo-controlled study with 62 participants. Across the three studies, participants experienced an average 67% reduction in pain scores and an average 50% increase in walking distance within 90 days, with measurable cartilage regeneration biomarkers in the placebo-controlled study and noticeable improvements reported as early as 15 days.* No adverse events were reported in any of the studies.*†

How does Cartigenix HP with RestorCel compare to glucosamine and chondroitin?

Glucosamine and chondroitin have been the dominant ingredients in joint supplementation for decades, but multiple meta-analyses have shown small or inconsistent effects compared to placebo. Cartigenix HP® with RestorCel™ takes a different approach: a proprietary blend of 13 standardized bioactives from Boswellia serrata and celery seed extract, evaluated as a finished formulation in three published human studies including a randomized, placebo-controlled trial, with measurable improvements in pain scores, walking distance, and (in the placebo-controlled study) cartilage regeneration biomarkers within 90 days.*†

What is the difference between supporting joint comfort and supporting cartilage regeneration?

Supporting joint comfort means addressing how the joint feels during daily activity — comfort, flexibility, ease of movement. Most general joint supplements aim at this layer. Supporting cartilage regeneration is narrower: it describes formulations studied for their ability to support the body’s renewal of cartilage matrix at the structural level, typically measured through cartilage turnover biomarkers, walking distance, imaging, and validated pain scales.* Until recently, cartilage regeneration was widely considered outside the scope of dietary supplements. Published research on Cartigenix HP with RestorCel has shown measurable changes in cartilage regeneration biomarkers in a placebo-controlled study.*†

How is Cartigenix HP with RestorCel taken?

Cartigenix HP with RestorCel is taken as 1 capsule twice daily with food, one in the morning and one in the evening, or as directed by a healthcare professional. Each bottle provides a 30-day supply. To align with the clinical research, a 90-day protocol is generally recommended. Calroy backs the product with a 45-day, 100% money-back guarantee.

Which botanicals and bioactives appear in cartilage-focused joint research?

Several standardized bioactive compounds appear in cartilage-focused research, including serratol from Boswellia serrata, boswellic acids (AKBA, KBA, BBA), and apiin and 3-n-butylphthalide from celery seed extract (Apium L. graveolens). RestorCel™, the proprietary blend in Cartigenix HP, is standardized for 13 such bioactives derived from Boswellia serrata and celery seed, with human studies on cartilage-relevant endpoints.*

Who should consider Cartigenix HP with RestorCel?

Cartigenix HP with RestorCel is appropriate for adults seeking to maintain joint flexibility, comfort, and mobility; active adults pairing daily movement with longevity goals; and individuals taking a proactive approach to long-term joint and cartilage health.* Adults in their 40s through 70s remaining active in tennis, pickleball, hiking, cycling, or strength training are common users. Individuals with specific medical conditions or those taking prescription medications should consult a healthcare professional before adding any supplement to their routine.

Are there side effects or interactions with Cartigenix HP with RestorCel?

In the three published human studies on Cartigenix HP with RestorCel, no adverse events were reported. The formulation is generally well tolerated and can typically be taken alongside other supplements. Individuals with specific medical conditions or those taking prescription medications should speak with a healthcare professional before adding any supplement to their routine.

What lifestyle factors support cartilage and joint health alongside supplementation?

Regular movement (walking, hiking, strength training) supports circulation and overall joint function. A nutrition pattern emphasizing antioxidant-rich whole foods, polyphenols, and omega-3-dense foods supports broader joint health. Healthy sleep routines, adequate hydration, and stress management round out a comprehensive plan. A cartilage-focused supplement layer is most effective when it sits alongside, not in place of, these foundational habits.*

Where is clinical research on cartilage-focused joint formulations published?

Clinical research on cartilage-focused joint formulations is published in peer-reviewed journals and conducted in partnership with academic institutions, clinicians, and researchers. The strongest evidence comes from studies that test the finished formulation rather than isolated ingredients, use validated outcome measures such as the WOMAC Pain Scale and 6-Minute Walk Test, and include placebo-controlled randomized designs. The three studies on Cartigenix HP with RestorCel are published in Pharmaceutical Research (Vaidya 2025), Indian Journal of Orthopaedics Surgery (Desai 2024), and International Journal of Orthopaedic Sciences (Desai 2022).

†As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores along with quality of life measures (Desai 2022).